Celgene clinical trials

Acquired by Bristol-Myers Squibb, Nov 20, 2019 · source ↗

The registry lists 480 studies whose lead sponsor is Celgene. 12 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 6, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 480. List all 480 → · All Bristol-Myers Squibb studies →

• Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseaseRecruitingNCT06808984Phase 2

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis SpasticityRecruitingNCT06782490Phase 2

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingNCT05519085Phase 3

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of Irafamdastat in Healthy Adult ParticipantsNot yet recruitingNCT07837115Phase 1

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T CellsRecruitingNCT03435796Phase 2/3

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT06988488Phase 1/2

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese ParticipantsNot yet recruitingNCT07700329Phase 1

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaRecruitingNCT04143724Phase 2

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical TrialsRecruitingNCT04064060Phase 3

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)RecruitingNCT06911502Phase 3

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial ReleaseAvailableNCT04771078

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• Individual Patient Compassionate Use of FedratinibAvailableNCT03723148

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT06764485Phase 3

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic GastroenteritisCompletedNCT05214768Phase 3

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaActive, not recruitingNCT06425302Phase 2

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT02546986Phase 2

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaActive, not recruitingNCT04884035Phase 1

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male ParticipantsTerminatedNCT07242781Phase 1

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell TransfusionsActive, not recruitingNCT04717414Phase 3

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple MyelomaTerminatedNCT04855136Phase 1

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell LymphomaActive, not recruitingNCT06356129Phase 3

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03651128Phase 3

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line SettingCompletedNCT01946477Phase 2

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell LymphomaCompletedNCT03703375Phase 3

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for TransplantCompletedNCT03106324

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell TransfusionsCompletedNCT04477850Phase 2

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT06163898Phase 1

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• Connect® MM- The Multiple Myeloma Disease RegistryTerminatedNCT01081028

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic EsophagitisCompletedNCT04991935Phase 3

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Active, not recruitingNCT04975997Phase 3

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological DisordersCompletedNCT02494258Phase 2

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple MyelomaActive, not recruitingNCT02773030Phase 1/2

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell TransplantationActive, not recruitingNCT06045806Phase 3

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple MyelomaCompletedNCT03601078Phase 2

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction ChemotherapyActive, not recruitingNCT02677922Phase 1/2

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Active, not recruitingNCT03930953Phase 1/2

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)TerminatedNCT03374085Phase 1/2

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic ImpairmentCompletedNCT06535399Phase 1

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative ColitisCompletedNCT02531126Phase 3

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT04428788Phase 1

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)Active, not recruitingNCT04245839Phase 2

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's DiseaseTerminatedNCT03440372Phase 3

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative ColitisCompletedNCT03915769Phase 3

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's DiseaseTerminatedNCT03464097Phase 3

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's DiseaseTerminatedNCT03467958Phase 3

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibCompletedNCT03952039Phase 3

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic SyndromesTerminatedNCT04951778Phase 1

  Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb

• A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin LymphomasCompletedNCT03575351Phase 3

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.CompletedNCT01996865Phase 3

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb

• Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete RemissionCompletedNCT01757535Phase 3

  Sponsor listed in the registry: Celgene · First submitted before Celgene became part of Bristol-Myers Squibb